Breaking AI & Tech News Analyzed

The Journey from Prototype to ClearanceBuilding a medical device is fundamentally different from standard software development. This week on Build Mode, host Isabelle Johannessen sat down with Robhy Bustami, co-founder and CEO of BioticsAI, to discuss the arduous path from a $100,000 prototype to FDA clearance. Bustami, a Startup Battlefield winner, detailed how his team is building an AI copilot for ultrasound designed to detect fetal abnormalities. The conversation revealed that the traditional startup mantra of 'move fast and break things' is obsolete in the medical sector, replaced by a necessity for extreme precision and coordination.Market Validation and Resource AllocationThe episode provides a strategic look at the 'data' driving medtech success. BioticsAI's recognition as a Startup Battlefield winner serves as a key validation of their technology's potential. However, Bustami emphasized that the primary data point for founders is not just market traction, but the successful navigation of complex regulatory pathways. This requires a significant reallocation of resources—shifting focus from rapid feature deployment to ensuring safety, reliability, and compliance with FDA standards.Shifting the MedTech CultureThe core impact of this discussion lies in the cultural shift it highlights for the industry. As timelines for FDA approval remain uncertain, the ability to maintain team morale and investor confidence becomes a critical operational metric. Bustami noted that building in a regulated industry requires a foundation of trust rather than speed. This signals a broader trend where medtech startups must balance the pressure of hyper-growth with the ethical and legal responsibilities of patient safety.The Future of AI in Healthcare RegulationLooking ahead, the medtech landscape will likely see a consolidation of companies that prioritize long-term compliance over short-term hype. As more AI copilots enter the market, the winners will be those founders who master the art of 'slow and steady' innovation. The next wave of medical breakthroughs will depend not just on algorithmic superiority, but on the ability to build sustainable organizations capable of weathering the regulatory storm.

The Challenges of FDA Approval Surviving the long road to FDA approval isn’t just about building great technology — it’s about keeping your team motivated, finding the right investors, and learning how to operate when timelines are uncertain. Lessons from BioticsAI This week on Build Mode, Isabelle Johannessen sits down with Robhy Bustami, co-founder and CEO of BioticsAI, a Startup Battlefield-winning company building an AI copilot for ultrasound to help detect fetal abnormalities. From a $100,000 prototype to FDA clearance, Bustami shares what it actually takes to build in one of the most regulated industries in the world. Building a Medtech Startup In this episode, they break down what it really looks like to build a medtech startup, including where you can’t “move fast and break things” and that every milestone takes time, coordination, and trust. Key Takeaways Team motivation is crucial during the long FDA approval process Finding the right investors is essential for medtech startups Adaptability is key when dealing with uncertain timelines Future Outlook As the medtech industry continues to evolve, startups like BioticsAI will play a critical role in shaping the future of healthcare technology. With the right approach and mindset, these companies can overcome the challenges of FDA approval and make a lasting impact.

Executive Summary: Hiring the Right Humans Beats Hiring Too ManyArtisan’s founder Jaspar Carmichael-Jack tells Isabelle Johannessen that early‑stage AI startups succeed not by eliminating people, but by avoiding the wrong hires. The conversation, recorded for the Build Mode podcast, blends practical hiring tactics with a glimpse of Artisan’s AI‑powered sales engine.Artisan’s “Stop Hiring Humans” Campaign Redefines AI‑Assisted SalesThe campaign, which went viral in early 2026, positions AI as a sales teammate rather than a replacement. Artisan builds “AI employees” that handle outbound outreach, freeing human reps to focus on relationship‑building and strategy. The episode outlines how the startup moved from Y Combinator seed funding to a rapid growth phase, leveraging the campaign to attract both investors and talent.Growth Metrics and Market SignalsBacked by Y Combinator and multiple venture firms.Series A closed in Q1 2026, raising $15 million.Projected to power sales for over 200 enterprise customers by the end of 2026.Upcoming appearance at TechCrunch Disrupt 2026 (Oct 13‑15, San Francisco) with a 15% ticket discount using code buildmode15.Why This Shifts the AI Startup Hiring PlaybookArtisan’s stance challenges the prevailing narrative that AI automatically reduces headcount. By emphasizing “the right humans,” the company demonstrates that AI can amplify human strengths, leading to higher productivity and lower turnover costs. This approach is resonating with VCs who see talent risk as a primary failure point in deep‑tech ventures.Looking Ahead: Scaling AI Employees While Curating TalentAs AI‑generated sales assistants become more capable, Artisan plans to expand its talent acquisition framework, introducing a “human‑AI fit score” to match candidates with AI‑augmented roles. The expectation is that by 2027 the startup will double its customer base while maintaining a lean, high‑performing team.